Matthew Barnett, MD
Family Medicine · Magnolia, ARNPI 1013953157
Payments from drug & device makers
Across 471 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$735
- Pfizer$733
- Novo Nordisk$578
- Lilly USA, LLC$532
- Amgen$384
- Astellas Pharma US Inc$384
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,77699%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $735 |
| Pfizer | 53 | $733 |
| Novo Nordisk | 41 | $578 |
| Lilly USA, LLC | 45 | $532 |
| Amgen(2 entities) | 27 | $384 |
| Astellas Pharma US Inc | 25 | $384 |
| Johnson & Johnson | 24 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $275 |
| GSK | 17 | $270 |
| Boehringer Ingelheim | 18 | $270 |
| Novartis | 22 | $258 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $248 |
| AstraZeneca(2 entities) | 16 | $236 |
| Merck | 14 | $234 |
| Abbott | 11 | $228 |
| Exact Sciences | 12 | $183 |
| Amarin Pharma, Inc. | 8 | $134 |
| E.r. Squibb & Sons, L.L.C. | 9 | $131 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $114 |
| Dexcom, Inc. | 6 | $93 |
| Genentech USA, Inc. | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Sunovion Pharmaceuticals Inc. | 4 | $51 |
| Medtronic | 3 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Biogen | 1 | $12 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Kyowa Kirin, Inc. | 1 | $12 |
How this compares
$6,825 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 161 | $107,559 |
| OzempicSemaglutide | 75 | $87,460 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $69,789 |
| FarxigaDapagliflozin Propanediol | 66 | $60,883 |
| TrulicityDulaglutide | 44 | $46,310 |
| MounjaroTirzepatide | 37 | $43,069 |
| LinzessLinaclotide | 30 | $28,501 |
| JanuviaSitagliptin Phosphate | 30 | $23,412 |
| EntrestoSacubitril/Valsartan | 18 | $22,872 |
| JardianceEmpagliflozin | 26 | $21,224 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $19,734 |
| RexultiBrexpiprazole | 12 | $18,237 |
| MyrbetriqMirabegron | 20 | $12,581 |
| XareltoRivaroxaban | 19 | $10,617 |
| Bydureon BciseExenatide Microspheres | 13 | $10,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $733 | $116,148194 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $270 | $89,523115 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $532 | $89,37881 claims |
| Novo NordiskOzempic | $578 | $87,46075 claims |
| AstraZenecaFarxiga, Symbicort | $236 | $64,89883 claims |
| AbbVieLinzess, Savella | $735 | $34,65843 claims |
| MerckJanuvia | $234 | $23,41230 claims |
| NovartisEntresto | $258 | $22,87218 claims |
| Boehringer IngelheimJardiance | $270 | $21,22426 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $13 | $18,23712 claims |
| Astellas Pharma US IncMyrbetriq | $384 | $12,58120 claims |
| Johnson & JohnsonXarelto | $303 | $10,61719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Magnolia
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
- Christopher BrownJonesboro$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.